CANSF / Willow Biosciences reports record revenue in 2022; completes development and manufacturing process in pilot scale for Cannabigerol

Willow Biosciences Inc (TSX:WLLW, OTCQB:CANSF) told investors it has partnered with Spanish life science company Suanfarma to bring sustainably source more_horizontal

Willow Biosciences Inc (TSX:WLLW, OTCQB:CANSF) announced a non-brokered private placement offering of convertible debenture units, with the goal of ra more_horizontal

Willow Biosciences Inc (TSX:WLLW, OTCQB:CANSF) said it has successfully completed research and development on its program to produce ursodeoxycholic more_horizontal

Willow Biosciences Inc (TSX:WLLW, OTCQB:CANSF) told investors it has filed a patent application for a process it has developed to produce corticostero more_horizontal

Willow Biosciences Inc (TSX:WLLW, OTCQB:CANSF) announced it has engaged an advisor to assist it with a review of opportunities to enhance value for it more_horizontal

Willow Biosciences Inc (TSX:WLLW, OTCQB:CANSF)' Canadian-listed shares had added more than 23% in the early afternoon on Monday after it announced th more_horizontal

Willow Biosciences Inc (TSX:WLLW, OTCQB:CANSF) has announced a collaboration with an unnamed Nasdaq-listed biopharma company to develop new sustainab more_horizontal

Willow Biosciences told investors that during the second quarter, it closed three new contracts that are expected to bring in more than $1 million in more_horizontal